Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
83.30
USDSponsored
+0.02
+0.02%
Jul 30, 15:59 UTC -4
Closed
Pre-Market
83.50
+0.20
+0.24%
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 31 of 42 last estimates.
74%
Next Report
Next Week
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$415.64M
/$1.87
Implied change from Q1 26 (Revenue/ EPS)
+10.34%
/+16.87%
Implied change from Q2 25 (Revenue/ EPS)
+27.61%
/+21.43%
Halozyme Therapeutics, Inc. earnings per share and revenue
On May 11, 2026, HALO reported earnings of 1.60 USD per share (EPS) for Q1 26, beating the estimate of 1.56 USD, resulting in a 2.52% surprise. Revenue reached 376.71 million, compared to an expected 366.23 million, with a 2.86% difference. The market reacted with a +6.81% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 1.87 USD, with revenue projected to reach 415.64 million USD, implying an increase of 16.87% EPS, and increase of 10.34% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.41
Actual
$0.92
Surprise
+122.65%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.52
Actual
$14.29
Surprise
+35.73%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.84
Surprise
+16.03%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.02
Surprise
-0.50%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Halozyme Therapeutics, Inc. reported EPS of $1.60, beating estimates by 2.52%, and revenue of $376.71M, 2.86% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved up 6.81%, changed from $66.41 before the earnings release to $70.93 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $1.87 and revenue of $415.64M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement